Evidence map›Paper›PMID 34086838›Full record

ArticlePLoS pathogens2021

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.

Fangping Cai, Wei-Hung Chen, Weimin Wu, Julia A Jones, Misook Choe, Neelakshi Gohain, Xiaoying Shen, Celia LaBranche, Amanda Eaton, Laura Sutherland and 17 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Fangping CaiDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Wei-Hung ChenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.ORCID 0000-0003-3724-9195
Weimin WuCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America.
Julia A JonesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-4900-5406
Misook ChoeEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.ORCID 0000-0003-0243-5203
Neelakshi GohainEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.ORCID 0000-0003-1370-312X
Xiaoying ShenDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-8387-3952
Celia LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-6653-6655
Amanda EatonDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0003-3064-2947
Laura SutherlandDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Esther M LeeDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Giovanna E HernandezDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0001-5498-3469
Nelson R WuDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-2612-8729
Richard ScearceDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.ORCID 0000-0001-6444-3562
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-3890-5855
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.ORCID 0000-0002-8796-1714
Kevin WieheDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Georgia D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Kshitij WaghLos Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Bette KorberLos Alamos National Laboratory, Los Alamos, New Mexico, United States of America.ORCID 0000-0002-2026-5757
Mattia BonsignoriDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0003-2973-2101
David C MontefioriDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Natalia de ValCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America.
M Gordon JoyceEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.ORCID 0000-0002-6808-7232
Kevin O SaundersDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0001-7399-7954
Duke Medical Center · USHenry M. Jackson Foundation · USBeth Israel Deaconess Medical Center · USLeidos (United States) · USLos Alamos National Laboratory · USNational Institutes of Health · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MONTEFIORI, DAVID C · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
HIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5M
Origin and maturation of protective memory B cell responses against pathogenic viruses in natural infections and upon vaccination.ZIAAI001342 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BONSIGNORI, MATTIA · 2021 to 2025
$7.0M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI120801NIAID NIH HHS R37 AI150590NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

A primary goal of HIV-1 vaccine development is the consistent elicitation of protective, neutralizing antibodies. While highly similar neutralizing antibodies (nAbs) have been isolated from multiple HIV-infected individuals, it is unclear whether vaccination can consistently elicit highly similar nAbs in genetically diverse primates. Here, we show in three outbred rhesus macaques that immunization with Env elicits a genotypically and phenotypically conserved nAb response. From these vaccinated macaques, we isolated four antibody lineages that had commonalities in immunoglobulin variable, diversity, and joining gene segment usage. Atomic-level structures of the antigen binding fragments of the two most similar antibodies showed nearly identical paratopes. The Env binding modes of each of the four vaccine-induced nAbs were distinct from previously known monoclonal HIV-1 neutralizing antibodies, but were nearly identical to each other. The similarities of these antibodies show that the immune system in outbred primates can respond to HIV-1 Env vaccination with a similar structural and genotypic solution for recognizing a particular neutralizing epitope. These results support rational vaccine design for HIV-1 that aims to reproducibly elicit, in genetically diverse primates, nAbs with specific paratope structures capable of binding conserved epitopes.

Indexed as

AIDS VaccinesAnimalsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansMacaca mulattaAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID34086838
PMCPMC8216552
OpenAlexW3164959753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.